Pharsight

Drugs that contain Apomorphine Hydrochloride

1. Kynmobi patents expiration

KYNMOBI's oppositions filed in EPO
KYNMOBI Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11077068 SUNOVION PHARMS INC Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
Feb, 2022

(2 years ago)

US9931305 SUNOVION PHARMS INC Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
Feb, 2022

(2 years ago)

US10888499 SUNOVION PHARMS INC Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
Feb, 2022

(2 years ago)

US9855221 SUNOVION PHARMS INC Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
Feb, 2022

(2 years ago)

US8663687 SUNOVION PHARMS INC Film compositions for delivery of actives
Feb, 2023

(1 year, 22 days ago)

US8765167 SUNOVION PHARMS INC Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
Feb, 2024

(4 days ago)

US8603514 SUNOVION PHARMS INC Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
Apr, 2024

(a month from now)

US10821074 SUNOVION PHARMS INC Sublingual and buccal film compositions
Aug, 2029

(5 years from now)

US9283219 SUNOVION PHARMS INC Sublingual films
Jun, 2030

(6 years from now)

US9669021 SUNOVION PHARMS INC Sublingual apomorphine
Jun, 2030

(6 years from now)

US9669019 SUNOVION PHARMS INC Sublingual apomorphine
Jun, 2030

(6 years from now)

US10420763 SUNOVION PHARMS INC Sublingual apomorphine
Jun, 2030

(6 years from now)

US9326981 SUNOVION PHARMS INC Sublingual apomorphine
Jun, 2030

(6 years from now)

US9044475 SUNOVION PHARMS INC Sublingual apomorphine
Jun, 2030

(6 years from now)

US8846074 SUNOVION PHARMS INC Sublingual films
Dec, 2031

(7 years from now)

US8414922 SUNOVION PHARMS INC Sublingual films
Dec, 2031

(7 years from now)

US11419769 SUNOVION PHARMS INC Sublingual films
Dec, 2031

(7 years from now)

US10959943 SUNOVION PHARMS INC Methods of treating Parkinson's disease by administration of apomorphine to an oral mucosa
Apr, 2036

(12 years from now)

US10449146 SUNOVION PHARMS INC Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
Apr, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) May 21, 2023

Market Authorisation Date: 21 May, 2020

Treatment: Treatment of 'off' episodes in patients with parkinson's disease

Dosage: FILM;SUBLINGUAL

More Information on Dosage

KYNMOBI family patents

Family Patents